New cancer drug YL201 enters human testing for advanced tumors
NCT ID NCT06057922
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an experimental drug, YL201, in about 990 people with advanced solid tumors like lung, prostate, and liver cancers. The goal is to check safety and see if tumors shrink. It is an early-stage trial, so the drug is not yet proven to work.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- YL201 (an experimental drug given by IV infusion every 3 weeks)
- What this could lead to
- If it works, this could point toward a new treatment option for several advanced cancers that have stopped responding to other therapies.
- What could go wrong
- This is an early-phase trial (Phase 1/2) with a small number of participants, so the drug may not shrink tumors or may cause significant side effects. Success is far from guaranteed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Cancer Hospital and Institute of Guangzhou Medical University
Guangzhou, Guangdong, China
-
Affiliated Cancer Hospital of Guangxi Medical University
Nanning, Guangxi, China
-
Affiliated Hospital of Chengde Medical University
Chengde, Hebei, China
-
Affiliated Hospital of Jiangnan University
Wuxi, Jiangsu, China
-
Anhui Provincial Cancer Hospital
Hefei, Anhui, China
-
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China
-
Dongguan People's Hospital
Dongguan, Guangdong, China
-
First Affiliated Hospital of Gannan Medical University
Ganzhou, Jiangxi, China
-
Fujian Cancer Hospital
Fuzhou, Fujian, China
-
Harbin Medical University Cancer Hospital
Haerbin, Heilongjiang, China
-
Henan Cancer Hospital
Zhengzhou, Henan, China
-
Hunan Cancer Hospital
Changsha, Hunan, China
-
Jiangmen Central Hospital
Jiangmen, Guangdong, China
-
Jiangxi Cancer Hospital (Jiangxi Second People's Hospital)
Nanchang, Jiangxi, China
-
Jiangyin People's Hospital
Wuxi, Jiangsu, China
-
Liaoning Cancer Hospital and Institute
Shenyang, Liaoning, China
-
Linyi Cancer Hospital
Linyi, Shandong, China
-
Liuzhou People's Hospital
Liuzhou, Guangxi, China
-
Liuzhou Worker's Hospital
Liuzhou, Guangxi, China
-
Nantong Tumor Hospital
Nantong, Jiangsu, China
-
Peking University People's Hospital
Beijing, Beijing Municipality, China
-
Shandong Cancer Hospital and Institute
Jinan, Shandong, China
-
Shandong Provincial Hospital
Jinan, Shandong, China
-
Shanxi Cancer Hospital
Datong, Shanxi, China
-
Sichuan Cancer Hospital
Chengdu, Sichuan, China
-
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Guangzhou, Guangdong, China
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510000, China
-
Taizhou Hospital of Zhejiang Province
Taizhou, Zhejiang, China
-
The Fifth Affiliated Hospital Sun Yat-Sen University
Zhuhai, Guangdong, China
-
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
-
The First Affiliated Hospital of Hainan Medical University
Haikou, Hainan, China
-
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China
-
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
-
The First Affiliated Hospital of USTC
Hefei, Anhui, China
-
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China
-
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, Henan, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
-
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
-
The First Hospital of Jilin University
Changchun, Jilin, China
-
The First People's Hospital of Changzhou
Changzhou, Jiangsu, China
-
The Frist People's Hospital of Foshan
Foshan, Guangdong, China
-
The People's Hospital of Guangxi Zhuang Autonomous Region
Nanning, Guangxi, China
-
The Second Affiliated Hospital of Guilin Medical University
Guilin, Guangxi, China
-
The Second Affiliated Hospital of the Chinese People's Liberation Army Air Force Medical University
Xian, Shanxi, China
-
The Second Hospital of Anhui Medical University
Hefei, Anhui, China
-
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China
-
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China
-
West China Hospital of Sichuan University
Huaxi, Sichuan, China
-
Xuzhou Central Hospital
Xuzhou, Jiangsu, China
-
Yuebei People's Hospital
Shaoguan, Guangdong, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Chemo combo vs. radioactive drug: which tames aggressive prostate cancer?
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can your own immune cells beat advanced cancer?
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Can targeted radiation boost Immunotherapy's power against head and neck cancer?